Physician profile
Gregory Ardigo
NPI 1548353956
$9,864.74
in general payments reported to CMS, 2019-2025
33 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $1,066 · 2021: $1,690 · 2022: $1,645 · 2023: $1,262 · 2024: $1,311 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,805 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,804.69 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,914.15 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $760.03 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $662.82 | 2019-2025 | |
| Gilead Sciences, INC. | $637.33 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.59 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $265.76 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $239.09 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $238.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $214.64 | 2019-2021 | |
| Lilly USA, LLC | $212.12 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $181.88 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $136.18 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $115.85 | 2023 | Idacio |
| Genzyme Corporation | $113.05 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $112.13 | 2019-2023 | Rebyota |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $79.78 | 2022 | |
| Nestle Healthcare Nutrition INC. | $64.44 | 2021-2023 | |
| Alfasigma USA, INC. | $60.20 | 2020 | |
| Qol Medical, LLC | $57.21 | 2019-2022 | |
| Vivus LLC | $54.62 | 2021-2025 | Qsymia |
| Allergan, INC. | $53.70 | 2019 | |
| Daiichi Sankyo INC. | $53.46 | 2021-2022 | |
| Medtronic, INC. | $49.31 | 2022-2025 | Pillcam |
| Phathom Pharmaceuticals, INC. | $39.38 | 2025 | Voquezna |
| Boston Scientific Corporation | $36.36 | 2022 | |
| Ethicon US, LLC | $33.24 | 2019 | |
| Redhill Biopharma INC. | $28.96 | 2021-2024 | Talicia |
| Evoke Pharma, INC. | $20.41 | 2024 | |
| Celltrion USA INC. | $19.94 | 2025 | Vegzelma |
| Ardelyx, INC. | $19.92 | 2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $16.77 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $16.39 | 2021 | |
| Concordia Pharmaceuticals INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ardigo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.